Last updated on March 2019

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease


Brief description of study

This is a multicenter, Phase 1b, randomized, doubleblind, placebocontrolled parallelgroup trial in adults with mild to moderate AD.

Detailed Study Description

This is a multicenter, Phase 1b, randomized, doubleblind, placebocontrolled parallelgroup trial in adults with mild to moderate AD. The primary endpoint is the change from the baseline CSF Amyloid beta oligomer concentration after dosing with CT1812 versus placebo. The change from baseline will be measured through a number of exploratory endpoints as indicated below. For each subject, the baseline CSF oligomer concentration will be computed as the average of the measurements from hours -4, -3, -2 and -1 and 0.

Clinical Study Identifier: NCT03522129

Find a site near you

Start Over

Clinilabs Drug Development Corporation

New York, NY United States
1.0miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.